Halozyme Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell HALO and other ETFs, options, and stocks.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. 

CEO
Helen I. Torley
CEOHelen I. Torley
Employees
350
Employees350
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
350
Employees350

HALO Key Statistics

Market cap
8.37B
Market cap8.37B
Price-Earnings ratio
28.17
Price-Earnings ratio28.17
Dividend yield
Dividend yield
Average volume
2.46M
Average volume2.46M
High today
$72.72
High today$72.72
Low today
$70.71
Low today$70.71
Open price
$71.71
Open price$71.71
Volume
787.70K
Volume787.70K
52 Week high
$82.22
52 Week high$82.22
52 Week low
$47.50
52 Week low$47.50

Stock Snapshot

With a market cap of 8.37B, Halozyme Therapeutics(HALO) trades at $70.91. The stock has a price-to-earnings ratio of 28.17.

On 2026-02-20, Halozyme Therapeutics(HALO) stock traded between a low of $70.71 and a high of $72.72. Shares are currently priced at $70.91, which is +0.3% above the low and -2.5% below the high.

Halozyme Therapeutics(HALO) shares are trading with a volume of 787.7K, against a daily average of 2.46M.

During the past year, Halozyme Therapeutics(HALO) stock moved between $47.50 at its lowest and $82.22 at its peak.

During the past year, Halozyme Therapeutics(HALO) stock moved between $47.50 at its lowest and $82.22 at its peak.

HALO News

TipRanks 2d
Halozyme Earnings Call Highlights Royalty-Fueled Growth

Halozyme Therapeutics ((HALO)) has held its Q4 earnings call. Read on for the main highlights of the call. President's Day Sale - 70% Off Unlock hedge fund-leve...

The Motley Fool 3d
Halozyme Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. Feb. 17, 2026 at 4:30 p.m. ET Call participants Chief Executive Officer — Helen I. Torley Chief Scientific Officer — Chris Wall...

Halozyme Q4 2025 Earnings Call Transcript
TipRanks 3d
Halozyme reports Q4 EPS 24c vs. $1.26 last year

Reports Q4 revenue $451.8M, consensus $446.14M. “2025 was a pivotal year for Halozyme (HALO) as we delivered record total revenue of $1.4B, which was the result...

Analyst ratings

56%

of 9 ratings
Buy
55.6%
Hold
33.3%
Sell
11.1%

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.